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The lymphoproliferative disorders continue to be the subject
of intensive and rewarding investigation. At a cellular level
much has been learned about their characteristics. Yet, two
decades since the introduction of combination chemotherapy
for the treatment of the more aggressive categories, there is
confusion and controversy as to whether the more recently
evolved intensive therapeutic approaches represent any ad-
vance at all. It is the very heterogeneity of these diseases at a
cellular level which largely explains the difficulty nowhere
are the potential fallacies of comparing the treatment of
patients by different groups and centres greater than in the
diverse malignancies which we group together as non-Hodg-
kin's lymphomas (NHL).
While large randomised trials such as those currently com-
paring second and third generation chemotherapy with simp-
ler cyclical combinations in intermediate and high grade
lymphomas are certainly overdue, we should not look to
them to provide all the answers in terms of the way ahead.
There is a growing realisation that a more selective approach
in treatment is now desirable the prime example being the
delineation of patients for whom intensive treatment includ-
ing allogeneic or autologous bone marrow transplantation is
appropriate.
There is now a wealth of data on prognostic factors to
form the basis of more critical comparisons of the results of
treatment between groups of investigators. It should also
prove possible to define, prospectively, subsets for which
different therapeutic approaches are needed.
Histopathological classification and pathological variables
Although discrete diagnostic entities have been described, the
fact that the proliferations at a cellular level represent what
may be considered as a discontinuous spectrum of disorders
has made for disagreement and confusion in their
classification. Groupings into categories which appeared to
carry an obviously poor prognosis in the short term became
distinguished from those with a more protracted natural
history. High grade lymphomas became synonymous with
'poor' prognosis, low grade with better or 'good' prognosis.
The pattern of survival curves based on the study of large
groups of patients has tended to support this broad concept,
as well illustrated by those of the Kiel group (Brittinger et
al., 1984). Comparisons between the results of treatment of
patients were hindered by the appreciable differencies in his-
tological approach, however, and this was not immediately
helped by the additional information provided by
immunophenotypic marker studies. It was in an attempt to
reconcile the principal histopathological systems of
classification and to recognise that there were more than two
broad groupings within the non-Hodgkin's lymphomas that
led to the consensus classification of the Working Formula-
tion (The non-Hodgkin's lymphoma pathologic classification
project, 1982). This system, based on light microscopy alone,
divides lymphomas into three major categories low,
intermediate and high grade. It does not, however, take
account of immunophenotypic markers, now well recognised
to be of prognostic significance. It also places diffuse large
cell lymphoma within the intermediate grade and puts
immunoblastic lymphoma, of similar prognosis, in the high
grade group. This has led to alternative schemas, notably
that of the NCI which refers to the three broad groupings as
'indolent', 'aggressive' and 'highly aggressive' (or leukaemia
like) DeVita et al., 1989; Urba et al., 1990). While there
would probably be general agreement that the approach to
treatment in diffuse, small, non-cleaved cell and lymphoblas-
tic NHL should be different to that for other high grade
NHL, the terminology carries implications as to the course of
disease and its prognosis which at best are approximations
and which can be misleading.
The additional information which became available as a
result of immunophenotyping added a further dimension to
histopathological diagnosis in NHL and the characterisation
of sub-categories of NHL has been facilitated by the
identification of cluster differentiation (CD) antigen markers.
Proliferative activity has been investigated by a variety of
methods and higher activity has been reported as being
generally associated with the less good prognostic categories
(Costa et al., 1981; Gerdes et al., 1984; Akerman et al.,
1987). Measurement of DNA content by flow cytometry with
determination of proliferation indices represents a further
step in classifying NHL and predicting outcome (Diamond et
al., 1982; Roos et al., 1985; Morgan et al., 1986; Williamson
et al., 1987). Within particular categories, for example mixed
centroblastic-centrocytic NHL, ploidy and proliferation index
have shown correlation with prognosis (Griffin et al., 1988).
To date, a clear picture of how these approaches could
contribute in the stratification of patients has not emerged. A
specific problem relates to the interpretation of flow
cytometry data, where the presence of reactive cells
represents an unknown variable, Methodology which more
specifically examines the malignant cells is required.
While the majority of NHL are B cell in origin, both the
immature and mature T cell diseases need to be charac-
terised. The peripheral T cell lymphomas represent a spec-
trum of disorders in which there is considerable variation in
possible outcome (Weisenburger et al., 1987).
Staging
The Ann Arbor classification which has been invaluable as
the basis for assessing the extent of Hodgkin's disease (HD)
(Carbone et al., 1971) has also been widely adopted in NHL.
Within any given stage there may be considerable differences
in the nature of the proliferation, the tumour cell load and
prognosis. Nevertheless, formal staging is a useful discipline
in establishing baseline data and helpful in comparing the
results of treatment in broadly comparable groups. Staging
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mainly serves to define the extent of disease in anatomical
terms (the indication of whether or not B symptoms are
present has been of practical value in HD, less so in NHL).
The clinical and surgical staging differences, which were high-
lighted by the policy of elective staging laparotomy in HD,
also apply to NHL, though surgical intervention is more
likely to be in order to establish a tissue diagnosis or a
therapeutic necessity in NHL. Stage migration due to the
improved accuracy of staging techniques is one reason why
historical comparisons may be invalid. The ground rules for
staging and the level of investigation need to be re-defined, as
has been recently done in relation to the staging of HD in the
Cotswold's Report (Lister et al., 1989; Crowther & Lister
1990). In therapeutic trials of combination chemotherapy in
the higher grades of NHL, it has been increasingly the prac-
tice to include patients of all stages except those with
localised non-bulky disease -a shift from the concentration
on stages III and IV in earlier studies. There is clearly a need
to move towards systems which take more account of
tumour bulk. Categorisations of patients as having low,
intermediate or high tumour burden have been put forward
as alternatives to the Ann Arbor system, notably a system
based on the number of extensively involved nodal areas and
the number of extranodal sites (Jagannath et al., 1986).
Reappraisal of staging, as has been done for HD, and prob-
ably a more radical shift to an international system which
grades tumour burden is now needed.
Cytogenetics
Many cytogenetic abnormalities have now been identified in
patients with the non-Hodgkin's lymphomas and a number
of specific associations identified, notably the characteristic
t(8;14) (q24;q32) translocation seen in the majority of
patients with small non-cleaved cell lymphomas of both Bur-
kitt and non-Burkitt type (Levine et al., 1985; Levine &
Bloomfield, 1990). In the follicular lymphomas the most
common abnormality recorded has been t(14;18) (q32;q21)
with deregulation of the B-cell leukaemia-lymphoma
oncogene, bc1-2 (Tsujimoto et al., 1985; Weiss et al., 1987).
The demonstration of this translocation in diffuse large cell
lymphomas has been taken to indicate their transformation
from follicular lymphoma (Aisenberg et al., 1988). There is
also accumulating evidence from molecular genetics, for
example the prevalence of c-myc rearrangements, to suggest
that primary gastrointestinal lymphomas are distinct from
primary nodal lymphomas (van Krieken et al., 1990). How-
ever, there is much to learn about the significance of these
molecular changes, as evidenced by the application of techni-
ques such as the polymerase chain reaction (PCR) which has
revealed that the bcl-2 translocation is a frequent occurrence
in HD as well as in follicular NHL (Stetler-Stevenson et al.,
1990).
There is, as yet, relatively limited information as to cor-
relation between such abnormalities and clinical course. It
has been found that, in general, increasing numbers of nor-
mal metaphases predict for better response rates and longer
survival. Several specific chromosomal abnormalities have
been found to carry apparent prognostic significance for
example, duplication of chromosome 3p being associated
with a relatively good prognosis, and duplication of chromo-
some 2p or bc1-2 rearrangement with poor prognosis (Yunis
et al., 1989). In practice the use of such information in
stratification and monitoring of patients is some way off.
Biochemical markers
There has been interest in the possibility of using one or
more biochemical markers as prognostic indicators and in
monitoring disease activity in lymphoproliferative diseases
for many years. If it were possible to define prognostic risk
groups using simple biochemical measurements obviating the
need for more extensive and less objective investigation, this
would indeed be an important advance in terms of a poten-
tially standard international approach. Swan et al. (1989)
have recently re-examined two already well known serum
markers, beta2 microglobulin (02m) and lactic dehydrogenase
(LDH). They concluded that these were the most significant
and independent variables for predicting time to treatment
failure (TTF) and survival. They found that serum P2m cor-
related with a simple estimation of tumour burden. Early
studies of P2m in NHL showed that there was broad corela-
tion between this serum marker and stage of disease (Child et
al., 1980; Hagberb et al., 1983). Anderson et al. (1983) also
found a highly significant association between P2m levels at
presentation and stage, presence of hepatomegaly and bone
marrow involvement. Despite this they did not demonstrate
statistically significant correlation between pretreatment ser-
um P2m levels and the achievement of CR, length of remis-
sion or survival. Hagberg et al. (1983) noted that the fre-
quency of complete remission was much lower and the
median survival significantly shorter in patients with stage
III/IV disease and high pretreatment levels than in those with
normal levels. There has been conflicting evidence as to any
possible relationship between histopathological category and
the incidence of raised serum P2m (Child & Kushwaha, 1984).
It is worth noting that the serum P2m has proved to be a
particular valuable prognostic indicator in myelomatosis,
where it widely used as a baseline prognostic indicator as
well as in monitoring (Child & Kushwaha, 1984). It is
presumed to correlate quite closely with tumour load. Of the
other lymphoproliferative disorders, chronic lymphatic leu-
kaemia is a disease in which a good correlation between
serum P2m levels and tumour load is apparent its measure-
ment provides an adjunct to clinical staging and serial
measurements can be helpful in disease monitoring (Spati et
al., 1980; Simonsson et al., 1980; Child & Kushwaha 1984).
Although it has been assumed that P2m is produced by the
'malignant' cells there may however be significant production
by other cells, of the lymphoid or monocyte-macrophage
series and increased serum levels may occur as a result of
viral infections, (Child & Kushwaha, 1984). It has been
demonstrated that cell surface expression of P2m shows
broadly considerable variation in patients with non-
Hodgkin's lymphomas, presumably reflecting the
heterogeneity of these disorders (Jones et al., 1987).
Of all the biochemical indicators investigated in the lym-
phomas, serum lactic dehydrogenase (LDH) has enjoyed the
most universal acceptance. Since the early report of Bierman
et al. (1957) many investigators have confirmed the value of
serum LDH as a prognostic tool, notably Ferraris et al.,
1979; Schneider et al., 1980; Fisher et al., 1981; Jagannath et
al., 1986 and Swan et al., 1989. In their study of patients
with advanced (stage III/IV) diffuse large cell NHL, Jagan-
nath et al. (1986) identified serum LDH and tumour burden
as independent risk factors for survival and devised a model
in which three distinct groups of patients could be identified
based on the serum LDH being normal or elevated and
tumour burden being low or heavy; the five year follow-up
data revealed survival as 87%, 48% and 20% for the high,
intermediate and low risk groups, respectively. LDH is not a
specific marker but would appear to be an enzyme coming
from the malignant cells, to reflect proliferative activity and,
when increased, to be associated with the occurrence of
systemic symptoms. For many years the erythrocyte sedimen-
tation rate (ESR), which had the merit of being a simple
routine investigation, was used as a crude indicator of disease
activity. It represents a complex interplay of factors including
the haematocrit and the levels of acute-phase reactants. Not
surprisingly the various acute-phase reactant proteins have
been investigated in both vertical and longitudinal studies. C
reactive protein, for example, is frequently increased in un-
treated lymphoma patients. In practice selected acute-phase
reactant proteins offer no advantage over determination of
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Miscellaneous factors
There have been many published reports on factors which
predict for response to treatment and for survival in NHL,
principally in the higher grades of disease treated by com-
bination chemotherapy. The data from earlier studies, for
example those of Fisher et al. (1977); Cabanillas et al. (1978)
and Fisher et al. (1981) have been added to but not substan-
tially contradicted by more recent investigations. In addition
to stage and serum LDH and P2m, patient gender, age,
performance status, bone marrow involvement, liver involve-
ment, disease bulk (variously assessed and measured) and
haematological indices have all been identified as carrying
prognostic significance. There is also evidence that, after
institution of treatment, rapidly responding patients have
more durable remissions (Armitage et al., 1986). Age is likely
to be an increasingly important consideration in new app-
roaches to treatment, though age-related differences in sur-
vival data may reflect causes other than death from NHL or
its treatment per se (Vose et al., 1988).
It is against this background of a plethora of data and the
practical experience ofmany centres and groups that we have
to consider new proposals for any prognostic index, as for
example that put forward by Hayward et al. (1991) in this
issue of the British Journal ofCancer. These authors highlight
the potential difficulties in comparing the results of treating
NHL in the face of 'selection pressures'. The Scotland and
Newcastle Lymphoma Group have collected data on 1,000
patients with intermediate and high grade non-Hodgkin's
lymphoma and their multivariate prognostic index is based
on analysis of 662 patients. Their additive index uses co-
efficients for deviations from best risk status. The infor-
mation required for this being age, performance status,
clinical stage, the presence/absence of B symtoms, white cell
count and evidence of liver and CNS involvement. Of these,
age, performance status and stage are the factors which
currently most commonly influence therapeutic approaches
and patient selection. The delineation of three distinct prog-
nostic groups when applied to a range of patient and treat-
ment subgroups is of interest and may be compared with the
stratification based on LDH and P2m reported by Swan et al.
(1989).
Conclusions
In attempting to facilitate comparative studies between
groups and centres there is a need to move towards a
uniform approach in staging NHL and in recording key
prognostic factors. On this basis it should prove possible to
define groups of patients for whom particular therapeutic
approaches, whether less or more intensive, are appropriate.
Patients identified as having poor prognostic features will
generally be regarded as candidates for intensive treatment,
possibly including allogeneic or autologous bone marrow
transplantation. However, in some older patients such fea-
tures may be an indication for gentler treatment or no treat-
ment at all.
Patients with the less aggressive forms of NHL are also
now being treated more intensively and, in weighing the
advantages of such approaches, it will be as important to
define prognostic categories as in the higher grades of di-
sease. Similar, but not necessarily identical, criteria will be
required.
Based on the accumulated information it is apparent that
there are several areas of potential agreement and others
where a uniform approach is neither feasible nor necessary:
The Working Formulation, now widely applied, requires cer-
tain amendments, notably the inclusion of immunoblastic
lymphoma in the same grade as other large cell lymphomas
with delineation from 'leukaemia-like' NHL. The
identification of particular sub-groups of NHL by immune
surface markers, especially the peripheral T cell lymphomas,
is also necessary.
The Ann Arbor system is not at all ideal in NHL but still
widely used. Pending its demise, systems which more accur-
ately reflect tumour burden should be used in parallel; bulky
intra-abdominal lymphomas are often selected out as carry-
ing poor prognosis regardless of conventional stage and gas-
trointestinal NHL may be better regarded as a separate
group, if only for the purpose of comparisons of treatment.
Age is increasingly likely to be a determinant in the inten-
sity of treatment; performance status should be uniformly
recorded as this may also determine therapeutic approach, at
least initially during remission induction.
The serum LDH, repeatedly shown to be a reliable if
non-specific marker, should be determined as a baseline
investigation; P2m is less generally available but, ideally,
should be recorded in parallel as more information is re-
quired as to its role and significance and it may well have
discriminant value.
The long list of objective and quantitative data identified
by multivariate analyses of different groups of patients
haemoglobin level, white cell/lymphocyte count, ESR/plasma
viscosity, sodium, albumin - will be routinely recorded but
are perhaps unlikely to be incorporated into a universally
agreed system.
Bone marrow and liver 'involvement' has often represented
subjective or, at best, semi-quantitative, information and
depends on the level and thoroughness of investigation.
Together with systemic or 'B' symptoms these factors seem
inappropriate for strict prognostic categorisation without fur-
ther re-definition.
The data based on the study of the malignant cell popula-
tions will, it is to be anticipated, ultimately provide more
specific prognostic information. The accumulation of detailed
clinical and laboratory investigatory data should be central in
the process of carrying out therapeutic trials and, no doubt,
the range and depth ofinvestigation will continue to increase.
Future treatment strategies may well be based on a quite
different data set to that now available. However, recent
debate and discussion, as at the Fourth International Con-
ference on Malignant Lymphoma in Lugano last June, would
suggest that we already have the basis of a 'common cur-
rency'. It is to be hoped that relatively simple criteria can be
agreed soon. The next step will be to encourage as many
groups and centres as possible to apply these prospectively in
pre-treatment stratification, or at the very least, in the pre-
sentation of the results of treatment.
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